{
  "citations" : [],
  "guideline" : {
    "objCls" : "Guideline Annotation",
    "id" : "PA166279621",
    "name" : "Annotation of CPIC Guideline for primaquine and G6PD",
    "alternateDrugAvailable" : true,
    "cancerGenome" : false,
    "crossReferences" : [
      {
        "id" : 1451896981,
        "resource" : "URL",
        "resourceId" : "https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/",
        "_url" : "https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/",
        "version" : 0
      }
    ],
    "descriptiveVideoId" : "AMnnwcsOpXI",
    "dosingInformation" : false,
    "hasTestingInfo" : false,
    "history" : [
      {
        "id" : 1452474664,
        "date" : "2024-05-15T09:42:34.378-07:00",
        "description" : "Added link to CPIC video",
        "type" : "Update",
        "version" : 0
      }
    ],
    "literature" : [
      {"id":15135762,"title":"Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype.","_sameAs":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281211","crossReferences":[{"id":1452680347,"resource":"PubMed Central","resourceId":"PMC10281211","_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281211"},{"id":1451882620,"resource":"PubMed","resourceId":"36049896","_url":"https://www.ncbi.nlm.nih.gov/pubmed/36049896"},{"id":1451882621,"resource":"DOI","resourceId":"10.1002/cpt.2735","_url":"http://dx.doi.org/10.1002%2Fcpt.2735"}],"objCls":"Literature","pubDate":"2023-05-01T00:00:00-07:00","terms":[{"id":1451577480,"resource":"PGx Paper Types","term":"Implementation","termId":"pgxPaperTypes:1451577480"}],"type":"Literature"}
    ],
    "otherPrescribingGuidance" : true,
    "pediatric" : true,
    "pediatricMarkdown" : {
      "id" : 1451994760,
      "html" : "<p>Guideline excerpt: &quot;There are data supporting or refuting certain drugs associated with increased risk of AHA in the setting of G6PD deficiency reported in pediatric patients (Table S1). There is no reason to think that genetically-based recommendations in this guideline should differ for children versus adults.&quot;</p>\n",
      "version" : 0
    },
    "recommendation" : true,
    "relatedAlleles" : [],
    "relatedChemicals" : [
      {
        "objCls" : "Chemical",
        "id" : "PA451103",
        "name" : "primaquine",
        "version" : 8
      }
    ],
    "relatedGenes" : [
      {
        "objCls" : "Gene",
        "id" : "PA28469",
        "symbol" : "G6PD",
        "name" : "glucose-6-phosphate dehydrogenase",
        "version" : 136
      }
    ],
    "source" : "CPIC",
    "summaryMarkdown" : {
      "id" : 1451899160,
      "html" : "<p>Primaquine should be avoided in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA) in most cases, with some exceptions for G6PD deficient patients without CNSHA. In patients with a G6PD variable or indeterminate phenotype an enzyme activity test should be carried out before initiating drug therapy.</p>\n<p>The G6PD gene is located on the X chromosome. Therefore, some patients will only have one copy, whereas others will have two copies. See full guideline for disclaimers, further details and supporting evidence.</p>\n",
      "version" : 0
    },
    "terms" : [],
    "textMarkdown" : {
      "id" : 1451899161,
      "html" : "<p>This annotation is based on the <a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/\" target=\"_blank\">Expanded CPIC&reg; Guideline for Medication Use in the Context of <em>G6PD</em> Genotype</a>. The CPIC authors evaluated the available evidence for the use of various drugs in patients carrying <em>G6PD</em> variants.</p>\n<h3 id=\"september-2022\">September 2022</h3>\n<ul>\n<li>The <a rel=\"noopener noreferrer\" href=\"https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.2735\" target=\"_blank\">Expanded CPIC&reg; Guideline for Medication Use in the Context of <em>G6PD</em> Genotype</a> has been published in Clinical Pharmacology and Therapeutics.</li>\n<li>These guidelines are applicable to:\n<ul>\n<li>adult patients</li>\n<li>pediatric patients</li>\n</ul>\n</li>\n<li>Excerpts from the guideline:\n<ul>\n<li>&quot;An additional step was added to this CPIC guideline to assign drugs into three groups: those that can be considered high risk for AHA in the presence of G6PD deficiency (and thus should generally be avoided), those that are considered medium risk in G6PD deficiency (and thus should be used with caution), and those that can be considered low-to-no risk (with no added risk of AHA in those that are deficient for G6PD versus those with normal G6PD status).&quot;</li>\n<li>&quot;In order to assign drugs into risk groups, the authors considered not only the strength of the evidence in the primary peer-reviewed literature, but also the frequency of drug use, the presence of regulatory agency warnings, and the presence or absence of a mechanism by which reactive oxygen species might be generated and contribute to hemolysis in G6PD deficiency (Supplement, Assigning Risk Level)&quot;</li>\n<li>&quot;<em><strong>Risk category for primaquine in G6PD deficiency.</strong></em> Primaquine at standard anti-relapse dosages of 0.25-0.5 mg/kg daily for 14 days for the treatment of <em>Plasmodium vivax</em> or <em>Plasmodium ovale</em> is considered in the high risk category because there is a high level of evidence linking it to AHA, but primaquine at lower doses is considered in either the medium or low-to-no risk category because it has been specifically studied in G6PD deficient patients (Table S1). The benefit of using primaquine may outweigh any possible risk of hemolysis, which is lower or negligible with these lower dose regimens.&quot;</li>\n</ul>\n</li>\n<li>Download and read:\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/G6PD/2022/36049896.pdf\" target=\"_blank\">Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of <em>G6PD</em> Genotype</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/G6PD/2022/36049896-supplement.pdf\" target=\"_blank\">2022 supplement</a></li>\n<li><a href=\"/page/g6pdRefMaterials\">G6PD Gene-Specific Information Tables</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/report/current/drug_resource/primaquine-Drug_Resource_Mappings.xlsx\" target=\"_blank\">Primaquine Drug Resource Mappings</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/report/current/test_alert/primaquine_Pre_and_Post_Test_Alerts.xlsx\" target=\"_blank\">Primaquine Pre and Post Test Alerts</a></li>\n</ul>\n</li>\n</ul>\n<h3 id=\"table-1-recommended-therapeutic-use-of-primaquine-in-relation-to-g6pd-phenotype\">Table 1: Recommended therapeutic use of primaquine in relation to <em>G6PD</em> phenotype</h3>\n<p><em>Adapted from Tables 1 and 4 of the guideline</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Predicted Phenotype</th>\n<th>Genotype<sup>a</sup></th>\n<th>Example genotypes<sup>b</sup></th>\n<th>Implications</th>\n<th>Therapeutic Recommendations</th>\n<th>Classification of recommendations<sup>c</sup></th>\n<th>Considerations</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Normal</td>\n<td>A person with one X chromosome carrying a non-deficient (class IV) allele<br/>OR<br/>A person carrying two non-deficient (class IV) alleles</td>\n<td>B, Sao Boria, IV<br/>&nbsp;<br/>B/B, B/Sao Boria, B/A, IV/IV</td>\n<td>Low risk of acute hemolytic anemia</td>\n<td>No reason to avoid primaquine based on G6PD status</td>\n<td>Strong</td>\n<td></td>\n</tr>\n<tr>\n<td>Deficient</td>\n<td>A person with one X chromosome carrying a deficient (class II-III) allele<br/>OR<br/>A person carrying two deficient (class II-III) alleles OR one class I allele and one class II or III allele</td>\n<td>A-, Orissa, Kalyan-Kerala, Mediterranean, Canton, Chatham, II, III<br/>&nbsp;<br/>A-/A-, A-/Orissa, Orissa/ Kalyan-Kerala, Mediterranean/ Mediterranean, Chatham /Mediterranean, Canton/ Viangchan, II/II, II/III, III/III, I/II, I/III</td>\n<td>High risk of acute hemolytic anemia with standard (or higher than standard) anti-relapse dosages for <em>Plasmodium vivax</em> or <em>Plasmodium ovale</em> of 0.25-0.5 mg/kg daily for 14 days</td>\n<td>Avoid primaquine, except in the following cases where established expert consensus guidelines for the treatment of malaria should be followed: (1) Treating <em>Plasmodium vivax</em> or <em>Plasmodium ovale</em> malaria for radical cure of liver-stage infections: 0.75 mg/kg once weekly x8 weeks (WHO) or 45 mg once weekly x8 weeks (CDC) - with close monitoring for hemolysis; (2) Treating <em>Plasmodium falciparum</em> malaria by using primaquine single dose as a gametocytocide at 0.25 mg/kg (WHO) - without need for monitoring for hemolysis.</td>\n<td>Strong</td>\n<td>Dosing recommendations for primaquine in patients with G6PD deficiency are derived from the malaria treatment guidelines issued by the <a rel=\"noopener noreferrer\" href=\"https://www.who.int/publications/i/item/guidelines-for-malaria\" target=\"_blank\">World Health Organization</a> and the <a rel=\"noopener noreferrer\" href=\"https://www.cdc.gov/malaria/resources/pdf/Malaria_Treatment_Guidelines.pdf\" target=\"_blank\">U.S. Centers for Disease Control and Prevention</a>.</td>\n</tr>\n<tr>\n<td>Deficient with CNSHA</td>\n<td>A person with one X chromosome carrying a deficient (class I) allele<br/>OR<br/>A person carrying two deficient (class I) alleles<sup>d</sup></td>\n<td>Bangkok, Villeurbanne, I<br/>&nbsp;<br/>Bangkok/Bangkok, Bangkok/Villeurbanne, I/I</td>\n<td>High risk of acute exacerbation of chronic hemolysis</td>\n<td>Avoid primaquine</td>\n<td>Strong</td>\n<td>The strength of evidence among patients with the G6PD Deficient phenotype provides strong rationale to also avoid primaquine in the setting of the more severe G6PD Deficient with CNSHA phenotype.</td>\n</tr>\n<tr>\n<td>Variable<sup>e</sup></td>\n<td>A person carrying one non-deficient (class IV) allele and one deficient (class I-III) allele</td>\n<td>B /Bangkok, B/Mediterranean, B/A-, IV/I, IV/II, IV/III</td>\n<td>Variable risk of acute hemolytic anemia</td>\n<td>To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.</td>\n<td>Moderate</td>\n<td>Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one nondeficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype; an enzyme activity test is needed to guide treatment in such cases.</td>\n</tr>\n<tr>\n<td>Indeterminate</td>\n<td>A person carrying at least one allele with uncertain function</td>\n<td>Dagua<br/>&nbsp;<br/>B/Dagua</td>\n<td>Unknown risk of acute hemolytic anemia</td>\n<td>To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.</td>\n<td>Moderate</td>\n<td></td>\n</tr>\n</tbody>\n</table>\n<p>CNSHA: chronic non-spherocytic hemolytic anemia<br />\n<sup>a</sup> WHO classifications from [Article:<a href=\"/pmid/22293322\">22293322</a>], other details from [Article:<a href=\"/pmid/4963040\">4963040</a>]. Class I alleles are extremely rare; the distinction between Class II and III alleles is not clear. Almost all patients will carry class II, III, or IV alleles.<br />\n<sup>b</sup> Due to the large number of G6PD alleles, other genotypes may be possible besides those given as examples here; see the <a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/report/current/allele_definition/G6PD_allele_definition_table.xlsx\" target=\"_blank\">G6PD Allele Definition Table</a> for a more comprehensive list of alleles and <a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/report/current/allele_function_reference/G6PD_allele_functionality_reference.xlsx\" target=\"_blank\">G6PD Allele Functionality Table</a> for their assigned function (WHO class). Note that some labs use the designation “B allele” to indicate an allele carrying no known class I-III variants. The <a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/report/current/frequency/G6PD_frequency_table.xlsx\" target=\"_blank\">G6PD Frequency Table</a> can be referenced for the frequency of G6PD alleles across major biogeographical groups.<br />\n<sup>c</sup> Rating scheme described in the Strength of Recommendations section in the <a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/G6PD/2022/36049896-supplement.pdf\" target=\"_blank\">guideline supplement</a>.<br />\n<sup>d</sup> Such genotypes have never been seen and are presumably exceedingly rare.<br />\n<sup>e</sup> Due to X-linked mosaicism, persons heterozygous (generally females) for one non-deficient (class IV) and one deficient (class I-III alleles) allele may display a normal or a deficient phenotype. It is therefore difficult to predict the phenotype of these individuals (see Supplement, G6PD Heterozygotes).</p>\n",
      "version" : 1
    },
    "version" : 3
  }
}